BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 15554360)

  • 1. Allelic frequency of the PAI-1 4G/5G promoter polymorphism in patients with type 2 diabetes mellitus and lack of association with PAI-1 plasma levels.
    Zietz B; Buechler C; Drobnik W; Herfarth H; Schölmerich J; Schäffler A
    Endocr Res; 2004 Aug; 30(3):443-53. PubMed ID: 15554360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diabetic retinopathy, promoter (4G/5G) polymorphism of PAI-1 gene, and PAI-1 activity in Pima Indians with type 2 diabetes.
    Nagi DK; McCormack LJ; Mohamed-Ali V; Yudkin JS; Knowler WC; Grant PJ
    Diabetes Care; 1997 Aug; 20(8):1304-9. PubMed ID: 9250459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PAI-1 4G/5G insertion/deletion promoter polymorphism and microvascular complications in type 2 diabetes mellitus.
    Funk M; Endler G; Exner M; Marculescu R; Endler L; Abrahamian H; Mauler H; Grimm A; Raith M; Mannhalter C; Prager R; Irsigler K; Wagner OF
    Wien Klin Wochenschr; 2005 Oct; 117(19-20):707-10. PubMed ID: 16416371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diabetic retinopathy, PAI-1 4G/5G and -844G/A polymorphisms, and changes in circulating PAI-1 levels in Tunisian type 2 diabetes patients.
    Ezzidi I; Mtiraoui N; Chaieb M; Kacem M; Mahjoub T; Almawi WY
    Diabetes Metab; 2009 Jun; 35(3):214-9. PubMed ID: 19419896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of plasminogen activator inhibitor-1 gene polymorphism and type 2 diabetic nephropathy.
    Xu F; Liu H; Sun Y
    Ren Fail; 2016; 38(1):157-62. PubMed ID: 26616527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PAI-1 Gene 4G/5G polymorphism and risk of type 2 diabetes in a population-based sample.
    Meigs JB; Dupuis J; Liu C; O'Donnell CJ; Fox CS; Kathiresan S; Gabriel SB; Larson MG; Yang Q; Herbert AG; Wilson PW; Feng D; Tofler GH; Cupples LA
    Obesity (Silver Spring); 2006 May; 14(5):753-8. PubMed ID: 16855181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasminogen activator inhibitor type 1 serum levels and 4G/5G gene polymorphism in morbidly obese Hispanic patients with non-alcoholic fatty liver disease.
    Espino A; Villagrán A; Vollrath V; Hanckes P; Salas R; Farah A; Solís N; Pizarro M; Escalona A; Boza C; Pérez G; Carrasco G; Padilla O; Miquel JF; Nervi F; Chavez-Tapia NC; Arab JP; Alvarez-Lobos M; Arrese M; Riquelme A
    Ann Hepatol; 2011; 10(4):493-501. PubMed ID: 21911891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genotype frequency of plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism in healthy Japanese males and its relation to PAI-1 levels.
    Matsubara Y; Murata M; Isshiki I; Watanabe R; Zama T; Watanabe G; Watanabe K; Ikeda Y
    Int J Hematol; 1999 Jan; 69(1):43-7. PubMed ID: 10641442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between gene polymorphism of the PAI-1 promoter and myocardial infarction.
    Fu L; Jin H; Song K; Zhang C; Shen J; Huang Y
    Chin Med J (Engl); 2001 Mar; 114(3):266-9. PubMed ID: 11780311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasminogen activator inhibitor-1 (PAI-1) promoter polymorphism and coronary artery disease in non-insulin-dependent diabetes.
    Mansfield MW; Stickland MH; Grant PJ
    Thromb Haemost; 1995 Oct; 74(4):1032-4. PubMed ID: 8560407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasminogen activator inhibitor-1 (PAI-1) promoter 4G/5G genotype and increased PAI-1 circulating levels in postmenopausal women with coronary artery disease.
    Grancha S; Estellés A; Tormo G; Falco C; Gilabert J; España F; Cano A; Segui R; Aznar J
    Thromb Haemost; 1999 Apr; 81(4):516-21. PubMed ID: 10235431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasminogen activator inhibitor-1 4G/5G polymorphism and retinopathy risk in type 2 diabetes: a meta-analysis.
    Zhang T; Pang C; Li N; Zhou E; Zhao K
    BMC Med; 2013 Jan; 11():1. PubMed ID: 23281898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prevalence of 4G5G polymorphism of plasminogen activator inhibitor-1 (PAI-1) gene in polycystic ovarian syndrome and its association with plasma PAI-1 levels.
    Diamanti-Kandarakis E; Palioniko G; Alexandraki K; Bergiele A; Koutsouba T; Bartzis M
    Eur J Endocrinol; 2004 Jun; 150(6):793-8. PubMed ID: 15191349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The 4G/5G sequence polymorphism in the promoter of plasminogen activator inhibitor-1 (PAI-1) gene: relationship to plasma PAI-1 level in venous thromboembolism.
    Stegnar M; Uhrin P; Peternel P; Mavri A; Salobir-Pajnic B; Stare J; Binder BR
    Thromb Haemost; 1998 May; 79(5):975-9. PubMed ID: 9609232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 4G/5G polymorphism of PAI-1 gene promoter and fibrinolytic capacity in patients with deep vein thrombosis.
    Sartori MT; Wiman B; Vettore S; Dazzi F; Girolami A; Patrassi GM
    Thromb Haemost; 1998 Dec; 80(6):956-60. PubMed ID: 9869167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of 4G/5G PAI-1 polymorphism on the response of PAI-1 activity to vitamin E supplementation in Type 2 diabetic patients.
    Testa R; Bonfigli AR; Sirolla C; Boemi M; Manfrini S; Mari D; Testa I; Sacchi E; Franceschi C
    Diabetes Nutr Metab; 2004 Aug; 17(4):217-21. PubMed ID: 15575342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 4G/5G PAI-1 promoter polymorphism and acute-phase levels of PAI-1 following coronary bypass surgery: a prospective study.
    Burzotta F; Iacoviello L; Di Castelnuovo A; Zamparelli R; D'Orazio A; Amore C; Schiavello R; Donati MB; Maseri A; Possati G; Andreotti F
    J Thromb Thrombolysis; 2003 Dec; 16(3):149-54. PubMed ID: 15087600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. C-reactive protein is directly related to plasminogen activator inhibitor type 1 (PAI-1) levels in diabetic subjects with the 4G allele at position -675 of the PAI-1 gene.
    Testa R; Bonfigli AR; Sirolla C; Marra M; Boemi M; Mari D; Sacchi E; Dolci A; Catalano A; Procopio A; Ceriello A
    Nutr Metab Cardiovasc Dis; 2008 Mar; 18(3):220-6. PubMed ID: 17433639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Promoter (4G/5G) plasminogen activator inhibitor-1 genotype and plasminogen activator inhibitor-1 levels in blacks, Hispanics, and non-Hispanic whites: the Insulin Resistance Atherosclerosis Study.
    Festa A; D'Agostino R; Rich SS; Jenny NS; Tracy RP; Haffner SM
    Circulation; 2003 May; 107(19):2422-7. PubMed ID: 12719278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PAI-1 promoter 4G/5G genotype as an additional risk factor for venous thrombosis in subjects with genetic thrombophilic defects.
    Seguí R; Estellés A; Mira Y; España F; Villa P; Falcó C; Vayá A; Grancha S; Ferrando F; Aznar J
    Br J Haematol; 2000 Oct; 111(1):122-8. PubMed ID: 11091191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.